Legend Biotech(DE:9LB)
€15.80-0.90 (-5.39%)
DE:9LB
Legend Biotech financials statements
€15.80
At close:-0.90 (-5.39%)
Legend Biotech (9LB) Ratios
1 Followers
Legend Biotech Ratios
DE:9LB's free cash flow for Q3 2026 was $-41.50M. For the 2026 fiscal year, DE:9LB's free cash flow was decreased by $-5.60M and operating cash flow was $-35.90M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.96 | 4.62 | 6.92 | 3.69 | 4.14 |
| Quick Ratio | 1.91 | 4.54 | 6.83 | 3.66 | 4.14 |
| Cash Ratio | 1.42 | 1.03 | 5.90 | 2.64 | 3.01 |
| Solvency Ratio | -0.37 | -0.24 | -0.83 | -0.73 | -1.10 |
| Operating Cash Flow Ratio | -0.16 | -0.52 | -1.82 | -0.68 | -0.87 |
| Short-Term Operating Cash Flow Coverage | -0.31 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 515.50M | $ 654.31M | $ 900.56M | $ 512.47M | $ 596.33M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.24 | 0.21 | 0.18 | 0.21 | 0.11 |
| Debt-to-Equity Ratio | 0.41 | 0.34 | 0.26 | 0.38 | 0.16 |
| Debt-to-Capital Ratio | 0.29 | 0.25 | 0.21 | 0.28 | 0.14 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.22 | 0.18 | 0.26 | 0.14 |
| Financial Leverage Ratio | 1.73 | 1.61 | 1.48 | 1.79 | 1.46 |
| Debt Service Coverage Ratio | -0.72 | -6.11 | -21.84 | -38.64 | -431.96 |
| Interest Coverage Ratio | -6.38 | -14.03 | -20.17 | -42.20 | -435.87 |
| Debt to Market Cap | 0.08 | 0.05 | 0.05 | 0.07 | 0.04 |
| Interest Debt Per Share | 2.36 | 2.04 | 3.98 | 3.71 | 1.76 |
| Net Debt to EBITDA | 2.10 | -0.56 | 1.99 | 1.20 | 1.44 |
| Profitability Margins | |||||
| Gross Profit Margin | 60.34% | 62.60% | 49.42% | 44.14% | 100.00% |
| EBIT Margin | -25.39% | -21.76% | -174.76% | -371.72% | -590.32% |
| EBITDA Margin | -22.58% | -18.04% | -167.59% | -356.00% | -570.10% |
| Operating Profit Margin | -13.27% | -48.35% | -154.13% | -389.40% | -569.97% |
| Pretax Profit Margin | -27.47% | -25.21% | -182.41% | -380.94% | -591.63% |
| Net Profit Margin | -28.85% | -28.22% | -181.75% | -381.48% | -586.38% |
| Continuous Operations Profit Margin | -28.85% | -28.22% | -181.75% | -381.48% | -586.38% |
| Net Income Per EBT | 105.02% | 111.95% | 99.64% | 100.14% | 99.11% |
| EBT Per EBIT | 207.03% | 52.15% | 118.35% | 97.83% | 103.80% |
| Return on Assets (ROA) | -17.12% | -10.60% | -28.03% | -33.54% | -36.05% |
| Return on Equity (ROE) | -29.62% | -17.01% | -41.41% | -59.97% | -52.69% |
| Return on Capital Employed (ROCE) | -12.44% | -21.78% | -26.93% | -44.10% | -44.06% |
| Return on Invested Capital (ROIC) | -9.59% | -21.70% | -26.78% | -43.95% | -43.63% |
| Return on Tangible Assets | -17.89% | -11.83% | -28.10% | -35.36% | -36.60% |
| Earnings Yield | -7.41% | -2.98% | -9.78% | -11.24% | -12.29% |
| Efficiency Ratios | |||||
| Receivables Turnover | 4.11 | 5.02 | 1.82 | 2.63 | 1.18 |
| Payables Turnover | 5.03 | 6.31 | 7.15 | 2.06 | 0.00 |
| Inventory Turnover | 12.75 | 9.81 | 7.42 | 6.31 | 0.00 |
| Fixed Asset Turnover | 2.56 | 3.11 | 1.50 | 0.72 | 0.48 |
| Asset Turnover | 0.59 | 0.38 | 0.15 | 0.09 | 0.06 |
| Working Capital Turnover Ratio | 1.27 | 0.55 | 0.27 | 0.15 | 0.11 |
| Cash Conversion Cycle | 44.79 | 51.99 | 199.21 | 19.70 | 310.49 |
| Days of Sales Outstanding | 88.79 | 72.67 | 201.05 | 138.87 | 310.49 |
| Days of Inventory Outstanding | 28.62 | 37.19 | 49.18 | 57.82 | 0.00 |
| Days of Payables Outstanding | 72.62 | 57.87 | 51.02 | 176.98 | 0.00 |
| Operating Cycle | 117.41 | 109.87 | 250.23 | 196.68 | 310.49 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.55 | -0.79 | -4.47 | -2.53 | -2.82 |
| Free Cash Flow Per Share | -0.91 | -0.86 | -4.73 | -2.81 | -3.46 |
| Dividend Paid and CapEx Coverage Ratio | -1.49 | -10.21 | -17.31 | -9.04 | -4.37 |
| Capital Expenditure Coverage Ratio | -1.49 | -10.21 | -17.31 | -9.04 | -4.37 |
| Operating Cash Flow Coverage Ratio | -0.24 | -0.41 | -1.20 | -0.71 | -1.61 |
| Operating Cash Flow to Sales Ratio | -0.10 | -0.23 | -1.38 | -1.72 | -2.88 |
| Free Cash Flow Yield | -4.19% | -2.66% | -7.85% | -5.63% | -7.43% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -13.59 | -33.55 | -10.22 | -8.89 | -8.13 |
| Price-to-Sales (P/S) Ratio | 3.89 | 9.49 | 18.58 | 33.93 | 47.69 |
| Price-to-Book (P/B) Ratio | 4.00 | 5.72 | 4.23 | 5.33 | 4.29 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -23.85 | -37.63 | -12.73 | -17.76 | -13.46 |
| Price-to-Operating Cash Flow Ratio | -39.89 | -41.31 | -13.47 | -19.72 | -16.54 |
| Price-to-Earnings Growth (PEG) Ratio | -0.21 | 0.50 | -2.21 | -3.48 | -1.23 |
| Enterprise Value Multiple | -15.15 | -53.14 | -9.10 | -8.33 | -6.92 |
| Enterprise Value | 3.52B | 6.01B | 4.35B | 3.47B | 2.72B |
| EV to EBITDA | -15.15 | -53.14 | -9.10 | -8.33 | -6.92 |
| EV to Sales | 3.42 | 9.59 | 15.25 | 29.64 | 39.47 |
| EV to Free Cash Flow | -20.94 | -38.03 | -10.45 | -15.51 | -11.14 |
| EV to Operating Cash Flow | -35.03 | -41.75 | -11.06 | -17.23 | -13.69 |
| Tangible Book Value Per Share | 5.03 | 4.74 | 14.17 | 8.50 | 10.64 |
| Shareholders’ Equity Per Share | 5.44 | 5.69 | 14.21 | 9.36 | 10.88 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.05 | -0.12 | 0.00 | -0.00 | 0.01 |
| Revenue Per Share | 5.58 | 3.43 | 3.24 | 1.47 | 0.98 |
| Net Income Per Share | -1.61 | -0.97 | -5.89 | -5.61 | -5.73 |
| Tax Burden | 1.05 | 1.12 | 1.00 | 1.00 | 0.99 |
| Interest Burden | 1.08 | 1.16 | 1.04 | 1.02 | 1.00 |
| Research & Development to Revenue | 0.40 | 0.66 | 1.34 | 2.87 | 4.55 |
| SG&A to Revenue | 0.33 | 0.45 | 0.37 | 0.69 | 0.68 |
| Stock-Based Compensation to Revenue | 0.00 | 0.11 | 0.17 | 0.29 | 0.29 |
| Income Quality | 0.34 | 0.91 | 0.76 | 0.45 | 0.49 |
Currency in USD

